Detalles de la búsqueda
1.
A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Lancet Gastroenterol Hepatol
; 9(5): 415-427, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402895
2.
Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
J Crohns Colitis
; 2023 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37941436
3.
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
EClinicalMedicine
; 64: 102249, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37842172
4.
Clinical course of inflammatory bowel disease and impact on liver disease outcomes in patients with autoimmune sclerosing cholangitis.
Clin Res Hepatol Gastroenterol
; 46(7): 101980, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35728760
5.
Treatment adaptations and outcomes of patients experiencing inflammatory bowel disease flares during the early COVID-19 pandemic: the PREPARE-IBD multicentre cohort study.
Aliment Pharmacol Ther
; 56(10): 1460-1474, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36196569
6.
Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study.
BMJ Open Gastroenterol
; 9(1)2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101886
7.
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
Lancet Gastroenterol Hepatol
; 7(4): 342-352, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123676
8.
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Lancet Gastroenterol Hepatol
; 7(11): 1005-1015, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36088954
9.
Diarrhoea and preadmission antibiotic exposure in COVID-19: a retrospective cohort study of 1153 hospitalised patients.
BMJ Open Gastroenterol
; 8(1)2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34489301
10.
Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
Lancet Gastroenterol Hepatol
; 6(4): 271-281, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33545083
11.
Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
J Crohns Colitis
; 14(10): 1385-1393, 2020 Oct 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32280965
12.
Editorial: the impact of COVID on the management of IBD flares: different care but similar outcomes-authors' reply.
Aliment Pharmacol Ther
; 57(1): 156-157, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36468219
13.
Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.
Aliment Pharmacol Ther
; 53(11): 1236-1240, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33961708
14.
What is the optimal treatment for anemia in inflammatory bowel disease?
Curr Drug Deliv
; 9(4): 356-66, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22023204
15.
Pharmacological management of diarrhea.
Gastroenterol Clin North Am
; 39(3): 495-507, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20951914
Resultados
1 -
15
de 15
1
Próxima >
>>